After back-to-back trial flops, Realm slashes its staff, halts research work and ponders a fire sale

Just days after reporting its second mid-stage trial failure in 5 months, little Realm Therapeutics $RLM is throwing in the towel.

The Phase II failure in atopic dermatitis — a crowded field which includes some notable giants — came on the heels of scrapping its Phase II program for PR013, a topical ophthalmic solution for the treatment of allergic conjunctivitis.